Supernus Pharmaceuticals, Inc.
Clinical trials sponsored by Supernus Pharmaceuticals, Inc., explained in plain language.
A pharmaceutical company specializing in central nervous system (CNS) treatments, including epilepsy and ADHD.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- ADHD drug SPN-812 tested for Long-Term safety in children Results expected Sep 2026 (estimated)
- New depression pill shows promise in Mid-Stage trial Results expected Dec 2026 (estimated)
- Parkinson's pump study tracks Real-Life symptom control Results expected Aug 2027 (estimated)
- New drug SPN-817 aims to tame Hard-to-Control seizures Results expected Aug 2027 (estimated)
-
New drug SPN-817 aims to tame Hard-to-Control seizures
Disease control Recruiting nowThis study tests whether SPN-817 can reduce seizure frequency in adults with focal onset seizures that don't respond well to current medications. About 216 participants will receive either SPN-817 or a placebo, and researchers will track seizure changes over 14 weeks. The goal is…
Phase 2 • Sponsor: Supernus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for Drug-Resistant epilepsy? phase 2 trial launches
Disease control Recruiting nowThis study tests a new drug called SPN-817 in 60 adults whose epilepsy does not improve with standard treatments. The main goal is to see if the drug is safe and tolerable. Researchers will also track whether it reduces the number of motor seizures. Participants take the drug as …
Phase 2 • Sponsor: Supernus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New epilepsy drug SPN-817 put to the test in Year-Long safety study
Disease control Recruiting nowThis study tests the long-term safety and effectiveness of a drug called SPN-817 in adults with focal onset seizures (a type of epilepsy). About 100 people who completed a previous SPN-817 study will take the drug for one year. Researchers will track side effects and measure chan…
Phase 2 • Sponsor: Supernus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Could this pill tame ADHD in kids as young as 4?
Symptom relief Recruiting nowThis study tests whether a medication called SPN-812 (viloxazine) can safely reduce ADHD symptoms in children aged 4 to 5. About 286 kids will receive either the drug or a placebo for 6 weeks. The goal is to see if the drug improves attention and reduces hyperactivity better than…
Phase 4 • Sponsor: Supernus Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
New depression pill shows promise in Mid-Stage trial
Symptom relief Recruiting nowThis study tests whether a new drug called SPN-821 can help adults with major depressive disorder who are already taking an antidepressant. About 230 participants will receive either SPN-821 or a placebo for 29 days. The main goal is to see if the drug reduces depression symptoms…
Phase 2 • Sponsor: Supernus Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Parkinson's pump study tracks Real-Life symptom control
Symptom relief Recruiting nowThis study follows 120 people with Parkinson's disease who are using a continuous apomorphine infusion pump (ONAPGO™) to see how it works in real-world settings. Researchers will track how long it takes to find the right dose, any changes to other Parkinson's medications, and how…
Sponsor: Supernus Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 07:55 UTC